Sarepta (SRPT) Stock Collapses 80% on FDA Bombshell – Is a Big Rebound Coming?
Sarepta Therapeutics shares plunged nearly 80% in 2025, falling from a high of $138.81 to around $15 after its Phase 3 ESSENCE trial failed and the FDA halted gene therapy trials following patient deaths. Q3 revenue beat estimates at $399.4 million, but the company posted a $179.9 million net loss. Sarepta restricted Elevidys sales to ambulatory patients after the FDA intervention. Analyst consensus is Hold, with a $34.50 average price target.